US20230256089A1 - Immunotherapy For The Treatment Of Allergic Disease - Google Patents
Immunotherapy For The Treatment Of Allergic Disease Download PDFInfo
- Publication number
- US20230256089A1 US20230256089A1 US17/945,504 US202217945504A US2023256089A1 US 20230256089 A1 US20230256089 A1 US 20230256089A1 US 202217945504 A US202217945504 A US 202217945504A US 2023256089 A1 US2023256089 A1 US 2023256089A1
- Authority
- US
- United States
- Prior art keywords
- allergen
- treatment
- vials
- vial
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000026935 allergic disease Diseases 0.000 title claims abstract description 23
- 238000011282 treatment Methods 0.000 title abstract description 41
- 238000009169 immunotherapy Methods 0.000 title description 18
- 239000013566 allergen Substances 0.000 claims abstract description 70
- 238000000034 method Methods 0.000 claims abstract description 44
- 230000001720 vestibular Effects 0.000 claims abstract description 21
- 239000000203 mixture Substances 0.000 abstract description 9
- 230000027288 circadian rhythm Effects 0.000 abstract description 5
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 238000012423 maintenance Methods 0.000 description 16
- 230000007958 sleep Effects 0.000 description 13
- 238000010790 dilution Methods 0.000 description 12
- 239000012895 dilution Substances 0.000 description 12
- 239000003085 diluting agent Substances 0.000 description 11
- 239000000284 extract Substances 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 210000000612 antigen-presenting cell Anatomy 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 230000002060 circadian Effects 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 230000000422 nocturnal effect Effects 0.000 description 7
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 230000007815 allergy Effects 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 210000001165 lymph node Anatomy 0.000 description 5
- 230000033764 rhythmic process Effects 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 244000025254 Cannabis sativa Species 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 238000013128 asthma control test Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108010065805 Interleukin-12 Proteins 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 210000002534 adenoid Anatomy 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000005178 buccal mucosa Anatomy 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- SQEHCNOBYLQFTG-UHFFFAOYSA-M lithium;thiophene-2-carboxylate Chemical compound [Li+].[O-]C(=O)C1=CC=CS1 SQEHCNOBYLQFTG-UHFFFAOYSA-M 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- 210000002741 palatine tonsil Anatomy 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 244000046151 Acer negundo Species 0.000 description 1
- 235000012092 Acer negundo ssp. interius Nutrition 0.000 description 1
- 235000009231 Acer negundo var texanum Nutrition 0.000 description 1
- 235000012089 Acer negundo var. negundo Nutrition 0.000 description 1
- 240000004731 Acer pseudoplatanus Species 0.000 description 1
- 235000002754 Acer pseudoplatanus Nutrition 0.000 description 1
- 241000223600 Alternaria Species 0.000 description 1
- 244000237958 Amaranthus spinosus Species 0.000 description 1
- 244000036975 Ambrosia artemisiifolia Species 0.000 description 1
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 244000251090 Anthemis cotula Species 0.000 description 1
- 235000007639 Anthemis cotula Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 229930194845 Bahia Natural products 0.000 description 1
- 241000238657 Blattella germanica Species 0.000 description 1
- 241001674044 Blattodea Species 0.000 description 1
- 210000005236 CD8+ effector T cell Anatomy 0.000 description 1
- 241000219502 Casuarina glauca Species 0.000 description 1
- 235000009344 Chenopodium album Nutrition 0.000 description 1
- 240000006122 Chenopodium album Species 0.000 description 1
- 241000222290 Cladosporium Species 0.000 description 1
- 241000223208 Curvularia Species 0.000 description 1
- 244000052363 Cynodon dactylon Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000238740 Dermatophagoides pteronyssinus Species 0.000 description 1
- 241001492222 Epicoccum Species 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- 101000890554 Homo sapiens Retinal dehydrogenase 2 Proteins 0.000 description 1
- 241000441510 Hormodendrum Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 241000189522 Iva Species 0.000 description 1
- 241000721662 Juniperus Species 0.000 description 1
- 235000014556 Juniperus scopulorum Nutrition 0.000 description 1
- 235000014560 Juniperus virginiana var silicicola Nutrition 0.000 description 1
- 244000147568 Laurus nobilis Species 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 241000208682 Liquidambar Species 0.000 description 1
- 235000006552 Liquidambar styraciflua Nutrition 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000014679 Morus rubra var. rubra Nutrition 0.000 description 1
- 235000014677 Morus rubra var. tomentosa Nutrition 0.000 description 1
- 235000009134 Myrica cerifera Nutrition 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000016499 Oxalis corniculata Nutrition 0.000 description 1
- 241000238675 Periplaneta americana Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000746983 Phleum pratense Species 0.000 description 1
- 235000016421 Pinus nigra Nutrition 0.000 description 1
- 235000010503 Plantago lanceolata Nutrition 0.000 description 1
- 244000239204 Plantago lanceolata Species 0.000 description 1
- 235000006485 Platanus occidentalis Nutrition 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 241000593917 Quercus virginiana Species 0.000 description 1
- 102100040070 Retinal dehydrogenase 2 Human genes 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 240000007001 Rumex acetosella Species 0.000 description 1
- 235000015761 Rumex acetosella Nutrition 0.000 description 1
- 235000008691 Sabina virginiana Nutrition 0.000 description 1
- 244000061457 Solanum nigrum Species 0.000 description 1
- 102000007451 Steroid Receptors Human genes 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- 230000029662 T-helper 1 type immune response Effects 0.000 description 1
- 241001138405 Taxodium distichum Species 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 241001149163 Ulmus americana Species 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 210000001971 anterior hypothalamus Anatomy 0.000 description 1
- 230000000454 anti-cipatory effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000008632 circadian clock Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 210000004544 dc2 Anatomy 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000004134 energy conservation Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 231100001039 immunological change Toxicity 0.000 description 1
- 210000000428 immunological synapse Anatomy 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 1
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- -1 isopropyl rubbing alcohol Chemical compound 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 102000003835 leukotriene receptors Human genes 0.000 description 1
- 108090000146 leukotriene receptors Proteins 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000009613 pulmonary function test Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000001520 savin Nutrition 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 235000003513 sheep sorrel Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Definitions
- the present invention generally relates to compositions and methods for the treatment of allergic disease.
- the pharmacological treatment of allergic diseases includes use of over-the-counter antihistamines, decongestants, and intranasal steroids, prescription nasal steroids, and leukotriene receptor blockers.
- domestic environmental intervention is designed to minimize exposure to indoor allergens, and when this fails or is insufficient, immunotherapy becomes the logical clinical step to follow.
- SCIT subcutaneous immunotherapy
- This treatment method is invasive, painful, and time-consuming.
- methods for subcutaneous immunotherapy administration have changed little since 1911.
- Injection-based methods typically consist of a buildup phase comprising about 100 to 400 separate injections over a period of 20 weeks (under ideal conditions with no interruptions or adverse reactions).
- Injection-based immunotherapy methods bear undesirable risks of adverse reactions that can be localized, generalized, near-fatal, or even fatal.
- improved methods of immunotherapy for treating allergic disease that are more amenable to modern lifestyles and carry much less risk to patients are needed.
- SLIT Sublingual immunotherapy
- SCIT remains the preferred treatment by health insurance companies in the United States.
- Circadian rhythms recur in physiological, biochemical, metabolic, behavioral, and other parameters. Circadian rhythms cycle approximately every 24 hours and persist in the absence of external time cues. These internally-generated rhythms are the product of a complex circadian timing system with a master pacemaker located in the suprachiasmatic nuclei of the anterior hypothalamus, synchronizing semi-automatic circadian pacemakers throughout the central nervous system and the periphery in order to impose a daily temporal architecture on mammalian physiology and behavior. This system allows physiological and cellular functions to be coordinated in time for both energy conservation processing and for the time segregation of opposing processes.
- Circadian rhythmicity also affects the function of the immune system with variations of immunocompetent cells and cytokines and assuring a well-timed anticipatory organization of biological processes that play a critical role in the preservation of homeostasis and defense.
- circadian clocks are regulated by a set of clock genes activated by transcription factors CLOCK and BAML1.
- CD4+ and CD8+ (cytotoxic)-naive, central memory, and effector memory T lymphocytes show peak numbers at night, whereas CD4+ effector T cells show no rhythm and CD8+ effector T cells show a low-amplitude rhythm with peaks during the day.
- Granulocytes, monocytes, and natural killer cells have shown their numbers to peak midday or late in the day. Serum levels and in vitro production of interferon gamma (IFN- ⁇ ), tumor necrosis factor alpha (TNF- ⁇ ), and IL-1, IL-2, IL-6, and IL-12 peak at night or early in the morning.
- IFN- ⁇ interferon gamma
- TNF- ⁇ tumor necrosis factor alpha
- IL-1, IL-2, IL-6, and IL-12 peak at night or early in the morning.
- Antigen presenting cells are involved in the capture and processing of allergens and the subsequent presentation of pathogen-derived peptides to native T cells in the lymph nodes, tonsils, and adenoids.
- APCs are located in the superficial layers of the oral mucosa and consist of CD 207+ Langerhans cells and CD 11b+, CD 68+, and CD206+ macrophages located in the lamina intestinal.
- APCs capture allergens by phagocytosis and by IgE mediation, as they are Fc ⁇ R1 positive.
- APCs exhibit a tolerogenic phenotype in that they produce IL-10 and TGF 13, and they express indoleamine 2,3-dioxygenase.
- the default response of oral APCs to allergens is intolerance as opposed to inflammation within the induction of IFN- ⁇ producing and IL-10 secreting TH-1 and regulatory T cells (Tregs), respectively, in draining cervical lymph nodes.
- Sleep supports the immunological synapse between APC and the T cells in lymph nodes.
- pro-inflammatory Th1-supporting hormones such as melatonin, GH, prolactin, and leptin
- anti-inflammatory hormones such as cortisol and catecholamine reach a nadir.
- This pro-inflammatory hormonal boost during sleep acts like an adjuvant, presumably on APCs, which show a sleep-dependent production of IL-12, which in turn supports Th1 lineage commitment (Dimitrov et al., 2007; Lange et al., 2006, 2011).
- the regulatory role of APCs mediating the sleep-associated peak of T cell cytokine production is substantiated by the fact that the rhythm in cytokine production of isolated CD4+ T cells is shifted by several hours (Bollinger et al., 2011).
- Th1 immune response In contrast, the initiation of a Th1 immune response that evolves more slowly requiring the interaction between APC and T cell in lymph nodes, protein biosynthesis, and cell proliferation is supported during sleep.
- the Th1 response is energy consuming and involves the release of pro-inflammatory mediators associated with pain, immobility, and malaise; therefore, its timing to the sleep period seems reasonable.
- B and T cells harbor an intrinsic clock, but additional regulatory influences of sleep, locomotor activity, hormonal changes, and APC activity entrain the rhythm of lymphocyte numbers and functions.
- adaptive immune responses such as the delayed-type hypersensitivity reaction, as well as the T cell and antibody response to immunizations, benefit from sleep.
- Such a time-limited boost of lymphocyte activity may serve immune homeostasis and maximize efficiency of the immune system.
- the oral cavity contains an abundance of immunologically-active tissues (tonsils, adenoids, and lymph nodes). This expedites the process of efficient antigen presentation.
- the low concentration of mast cells guarantees safe allergen administration via vestibular immunotherapy. According to Allam (Allergy 2008), there is a substantial concentration of dendritic cells in the oral vestibular space.
- the inventor of the embodiments disclosed herein discovered a new and improved method for treating allergic disease, which includes, inter alia, treating a patient at night using the compositions and methods described herein.
- the inventor also discovered that treating a patient at night via the oral vestibular space is an ideal protocol for the delivery of allergen-specific immunotherapy and other immunologic intervention.
- Embodiments of the present disclosure include a method for treating an allergic disease, the method comprising administering daily to a person in need thereof a first dosage of an allergen, the first dosage applied to the person’s sublingual space and progressively increasing in concentration per day over a time period of about four weeks; and administering daily to the person a second dosage of the allergen, the second dosage applied to the person’s oral vestibular space and remaining at a constant concentration per over a time period of about twelve weeks; wherein the administering steps comprise administering the allergen at night.
- Another embodiment of the present disclosure includes a method for treating allergic disease, the method comprising providing a serum to a patient, the serum including at least one allergen; and instructing the patient to self-administer at night a dosage of the serum, the instructing including defining a treatment period having a first phase and a second phase, wherein the dosage progressively increases during the first phase, and wherein the dosage remains constant during the second phase; wherein in the first phase the patient self-administers the serum to its sublingual space, and wherein in the second phase the patient self-administers the serum to its oral vestibular space.
- FIG. 1 is a depiction of a reduction in the total symptom score in patients treated in accordance with embodiments of the present disclosure
- FIG. 2 is a depiction of increased adherence to treatment in patients treated in accordance with embodiments of the present disclosure
- FIGS. 3 A and 3 B are depictions of a reduction in the total symptom score and adherence levels, respectively, in patients treated in accordance with embodiments of the present disclosure
- FIG. 4 is a comparison of total symptom score changes between patients treated with prior art methods and patients treated in accordance with embodiments of the present disclosure.
- FIG. 5 depicts changes in clinical parameters in 38 patients from inner city asthmatic patients treated with embodiments of the present disclosure.
- NVOT Nocturnal Immuno Vestibular Oral Therapy
- the dosages are delivered to the sublingual space during the buildup stage and later delivered to the vestibular space during a subsequent maintenance phase.
- Nocturnal administration for example, after sundown or otherwise determined upon consideration of the circadian rhythm(s) and sleep cycle(s) of a patient to be treated, maximizes the benefits of the natural immunological circadian cycles and minimizes disruption of the attachment of allergens in the mixture from the oral mucosa by eating or drinking.
- embodiments of the present disclosure include a method for treating a person with allergic disease, the method comprising administering to the person’s sublingual space a first dosage of an allergen; and administering to the person’s oral vestibular space a second dosage of the allergen.
- the allergen is administered at night so as to maximize the effectiveness of the treatment by exploiting the circadian rhythmicity of the patient’s immune system and reductions in oral mucosal disruptions during sleep.
- a concentration of the first dosage of the allergen may be increased over time, thereby permitting a gradual increase in the patient’s tolerance to the allergen.
- the first dosage of the allergen may be administered over a time period of about 4 weeks.
- the second dosage of the allergen, administered during a second phase of the treatment remains constant over time.
- the second dosage is administered over a time period of about 12 weeks.
- Another embodiment includes a method for treating allergic disease, the method comprising providing an allergen to a person, and instructing the person to self-administer the allergen at night.
- the instructing may include defining a treatment period having a first phase and a second phase, wherein in the first phase the person self-administers the allergen to its sublingual space, and wherein in the second phase the person self-administers the allergen to its oral vestibular space.
- a dosage of the allergen progressively increases.
- a dosage of the allergen is constant.
- the first phase spans a time period of about 4 weeks
- the second phase spans a time period of about 12 weeks.
- Yet another embodiment includes a method for treating allergic disease, the method comprising administering an allergen to a subject’s oral vestibular space.
- the treatment may be self-administered by the subject thereof.
- the method includes providing an allergen to a subject, and instructing the subject to administer the allergen to an oral vestibular space. Further, the physician or other health professional may instruct subject to only administer the allergen at night.
- Still yet another embodiment includes a method for treating an allergic disease, the method comprising providing an allergen to a person, and instructing the person to administer the allergen in accordance with a treatment plan, the treatment plan having a first phase and a second phase, the first phase including administering the allergen to the person’s sublingual space, the second phase including administering the allergen to the person’s oral vestibular space.
- time points for nocturnal administration of an allergen may vary, so long as the administration is timed to correlate with the subject’s immune system circadian cycles and/or sleep cycles as herein described or as otherwise understood in the art.
- the allergen may be any known allergen.
- the allergen may be at least one of a grass, an inhalant, a weed, a tree, a mold, or any other substance or extract thereof that causes an allergic reaction in a subject.
- the grass allergen may be a component of, or extract from, a grass such as Bahia, Bermuda, Johnson, Rye, or Timothy grass, or any other known grass and/or an extract therefrom.
- Exemplary inhalants include D. Farinea , D. Pteronyssinus , cat epithelium, dog epithelium, and/or German or American cockroach.
- Exemplary weeds include short ragweed, marsh elder, dog fennel, mugwort, baccahris, lambs quarter, spiny pigweed, sheep sorrel, nettle, and/or English plantain.
- Exemplary trees include Virginia live oak, red cedar, bald cypress, Australian pine, Bayberry, sweet gum, box elder, American elm, E. sycamore, and/or red mulberry.
- Exemplary molds include alternaria, penicillum mix, Cladosporium, Aspergilus mix, Helminlthosporium, Curvularia, Fusarium, Epicoccum, Pullularia, Hormodendrum, horse, and/or rabbit.
- an embodiment of the present disclosure may be prepared and administered in accordance with the following procedure.
- Vials 1 and 2 of the custom formulated serum are administered in progressively increasing dosages during the first 2 weeks of treatment.
- vials 3 and 4 are administered in progressively increasing dosages during weeks 3 and 4 of treatment.
- Vial 5, or “maintenance”, is started on week 5 and continues for the duration of treatment with daily administration. The maintenance vials last for 3 months.
- maintenance dosage is relocated to the oral vestibular space, which is the area between the buccal mucosa and the teeth. It extends posteriorly all the way to the 2nd and 3rd molar regions. This space is rich in dendritic cells, which are central antigen presenting cells for the immune processing of antigens.
- the maintenance dosage is one drop per vial per day, which is very easily accommodated in this small space. Patients are instructed to hold the drops in place for at least 10 to 20 minutes. Afterward, patients are instructed to move the retained allergen and saliva to the inner aspects of the upper and lower lips and buccal mucosa.
- the embodiments disclosed are believed to induce a decrease in eosinophilic infiltrates and allergen-specific Th2 CD 4+ T cell responses in target organs in parallel with induction of systemic Th1 and Treg responses, a decrease in specific IgE in serum and mucosa, and induction of allergen-specific IgA and IgG2.
- successful immunotherapy may be correlated with immune reorientation of existing allergen-specific Th2 responses toward Th1 and Treg protide.
- the embodiments disclosed also likely induce expression of C1q and stabilize in the blood of responders patients as well as down-regulation of markers of type 2 DC (CD141 and OX-402).
- new NIVOT treatment sets comprising four 10 mL vials filled with allergens formulated specifically to each patient’s specific allergies according to skin testing (or any other determination) are prepared in accordance with the following protocol.
- a possible total of 11 extracts of allergens consisting of molds and cockroach mix are mathematically divided into equal portions to fill a 10 mL vial.
- a possible total of four extracts of allergens consisting of inhalants including cat, dog, and dust mites are mathematically divided into equal portions to fill a 10 mL vial.
- Allergen stocks may be obtained from any commercial allergen supplier. After the stocks are made, they are lined up vertically starting from the bottom. The bottom vial is labeled as vial A and the top as vial D.
- a first vial is labeled vial #4 and will contain a 1:1 dilution.
- Fill each vial in that column with 0.75 mL of diluent by extracting 0.75 mL of diluent from the diluent bottle using a 1 mL mixing syringe with an attached 23 G ⁇ 1 ⁇ 2-inch needle and dispensing 0.75 mL of diluent into each of the 4 vials (A through D, if applicable).
- vials labeled #3 which will contain a dilution of 1:10
- vials labeled #2 which will contain a dilution of 1:100
- vials labeled #1 which will contain a dilution of 1:1000.
- Fill each of these vials with 2.25 mL of diluent by extracting 2 mL from the diluent bottle using a 5 mL mixing syringe with an attached 23 G ⁇ 1 ⁇ 2-inch needle and then extracting 0.25 mL from the diluent bottle using a 1 mL mixing syringe with an attached 23 G ⁇ 1 ⁇ 2-inch needle.
- the final step of the dilution process is adding the stock to the vials by extracting 0.75 mL of stock A using a 1 mL mixing syringe with a 23 G ⁇ 1 ⁇ 2-inch needle attached and dispensing 0.75 mL of stock into vial #4A for a dilution of 1:1. Repeat the process by extracting the same amount from stocks B, C, and D (if applicable) and dispensing it into the vials of set #4B, C, and D (if applicable).
- Each set of vials is packaged in a 13 mm box with a 13 mm tray insert that can hold up to 6 vials.
- Each box will contain vials from the same dilutions and stock. There will be five boxes made per patient for each new treatment. Box 1 will contain all of the vials from set #1 (1:1000), vials A through D (if applicable). Box 2 will contain all of the vials from set #2 (1:100), vials A through D (if applicable). Box 3 will contain all of the vials from set #3 (1:10), vials A through D (if applicable). Box 4 will contain all of the vials from set #4 (1:1), vials A through D (if applicable). Box 5 will contain all of the vials from set #5 “maintenance” (1.01), vials A through D (if applicable).
- Each box is labeled with the patient’s first and last name, what number vial the box contains (#1, #2, etc.), and the expiration date of the vials.
- Each box will also have a red warning label that reads: “Keep out of reach of children. Keep refrigerated.” All boxes may be held together by a rubber band and must be refrigerated at 40° F. or less at all times. Boxes should only be removed from the refrigerator when in use for treatment.
- a new patient comes in for an allergy checkup.
- the patient is then scheduled for follow up visit, which involves skin test.
- the results of the skin test aid in a determination of what allergens the patient is allergic to.
- This skin test informs the physician of which allergens to include in the treatment regimen.
- the identity of the allergens will be different for each patient depending on what they are allergic to.
- the patient will have another follow up visit to pick up the drops (total 4 vials).
- the first vial drop may be administered at the clinic under a physician’s observation. If the patient is able to tolerate this first dosage without an adverse reaction, this first dosage will become the patient’s starter dose. If the patient has an adverse reaction to the starter dose, the starter dose is diluted and the procedure is initiated again.
- the first four vials are in increasing dosage and will last about one month.
- the four patients experienced an average increase in TSS of 2.75 points while on SCIT.
- an average decrease in TSS of 6.5 points was measured.
- One of the patients was affected with asthma and was frustrated with lack of response while on SCIT.
- her Asthma Control Test (ACT) score improved by 12 points 1 month after the introduction of NIVOT with no changes made to her asthma controller medications. NIVOT was tolerated without any adverse events in all four patients.
- FIG. 2 depicts patients’ improved adherence to the treatment protocol of the present disclosure as compared to adherence to treatment regimens by patients treated with SCIT. After 7 weeks of treatment, 87% of the patients treated in accordance with embodiments of the present disclosure were still adhering to the treatment protocol, whereas only 57% present of patients treated with SCIT were still undergoing treatment. In fact, improved adherence to treatment can be measured at as early as one week after initiation of the treatment protocol.
- FIG. 3 A is a comparison of total symptom score between the general population, children, and Amerigroup® patients.
- the first maintenance doses were provided at one month after the start of treatment.
- all three groups showed a substantial decrease in total symptom score, and that decrease was maintained for at least one year following the initiation of treatment in accordance with the embodiments of the present disclosure.
- adherence levels for patients in this study were also within a desirable range.
- FIG. 4 is a comparison of total symptom scores between patients treated with the embodiments disclosed herein and patients treated with traditional SCIT.
- Patients in the two treatment groups each began treatment at a TSS of about 12-13.
- TSS TSS of about 12-13.
- At the beginning of the first maintenance dose patients exhibited comparable decreases in TSS.
- FIG. 5 depicts changes in clinical parameters in 38 patients from inner city asthmatic patients treated with embodiments of the present disclosure
- FEV1 Forced Expiratory Volume in the first second of a pulmonary function test (“PFT”), wherein the amount of air blown in 1 second is measured
- ACT Asthma Control Test (commercially available)
- TSS total symptom score
- NIVOT administered at bedtime should be considered as a viable alternative in the management of these patients. Nocturnal administration may have an impact on the effectiveness of NIVOT due to immunological changes associated with the circadian cycle of the immune system.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Compositions and methods for the treatment of allergic disease include treating a subject in need thereof with a dosage of an allergen, wherein the allergen is administered to the subject’s oral vestibular space. In a preferred embodiment, the allergen is administered at night, thereby exploiting circadian rhythms in the subject’s immune response and enhancing the effectiveness of the treatment.
Description
- This application is a divisional of, and claims priority to and the benefit of, U.S. Pat. Application Serial No. 15/912,904, filed Mar. 6, 2018, which itself claims priority to, and the benefit of, U.S. Provisional Pat. Application Serial No. 62/552,054, filed Aug. 30, 2017, the contents of which is incorporated by reference and commonly owned.
- The present invention generally relates to compositions and methods for the treatment of allergic disease.
- The rise in prevalence of allergic diseases is part of the new epidemic of non-communicable diseases associated with urbanization and progress, adoption of western lifestyles in developing countries, and exposure to various chemicals that are commonly used in current urban and developed environments. This rise in prevalence is associated with disruptions in the biome, excessive hygiene, and lack of exposure to natural environments such as barns, farms, and soil. Allergic diseases are thought to affect 20% to 30% of the population, but current numbers attest to an increase in the recent past. The cost of these diseases to society, healthcare systems, and affected individuals and their families is substantial.
- The pharmacological treatment of allergic diseases includes use of over-the-counter antihistamines, decongestants, and intranasal steroids, prescription nasal steroids, and leukotriene receptor blockers. Domestic environmental intervention is designed to minimize exposure to indoor allergens, and when this fails or is insufficient, immunotherapy becomes the logical clinical step to follow.
- The most widely used method of immunotherapy for the treatment of allergic disease is subcutaneous immunotherapy (“SCIT”), which utilizes allergen injections. This treatment method is invasive, painful, and time-consuming. Moreover, methods for subcutaneous immunotherapy administration have changed little since 1911. Injection-based methods typically consist of a buildup phase comprising about 100 to 400 separate injections over a period of 20 weeks (under ideal conditions with no interruptions or adverse reactions). Injection-based immunotherapy methods bear undesirable risks of adverse reactions that can be localized, generalized, near-fatal, or even fatal. In this context, improved methods of immunotherapy for treating allergic disease that are more amenable to modern lifestyles and carry much less risk to patients are needed.
- Sublingual immunotherapy (“SLIT”) is a somewhat newer treatment modality used to treat allergic disease. SLIT involves sublingual administration of a custom-formulated allergy serum over an extended period of time to gradually create immunity to a patient’s specific allergic triggers. This form of immunotherapy is much less invasive than allergy shots and requires less nursing staff and office visits, as the majority of the treatment is self-administered by patients at home. Unfortunately, however, SCIT remains the preferred treatment by health insurance companies in the United States.
- Circadian rhythms recur in physiological, biochemical, metabolic, behavioral, and other parameters. Circadian rhythms cycle approximately every 24 hours and persist in the absence of external time cues. These internally-generated rhythms are the product of a complex circadian timing system with a master pacemaker located in the suprachiasmatic nuclei of the anterior hypothalamus, synchronizing semi-automatic circadian pacemakers throughout the central nervous system and the periphery in order to impose a daily temporal architecture on mammalian physiology and behavior. This system allows physiological and cellular functions to be coordinated in time for both energy conservation processing and for the time segregation of opposing processes.
- Circadian rhythmicity also affects the function of the immune system with variations of immunocompetent cells and cytokines and assuring a well-timed anticipatory organization of biological processes that play a critical role in the preservation of homeostasis and defense. At the intracellular end, circadian clocks are regulated by a set of clock genes activated by transcription factors CLOCK and BAML1.
- For example, T and B lymphocyte concentrations are considerably higher at night. CD4+ (T helper) and CD8+ (cytotoxic)-naive, central memory, and effector memory T lymphocytes show peak numbers at night, whereas CD4+ effector T cells show no rhythm and CD8+ effector T cells show a low-amplitude rhythm with peaks during the day. Granulocytes, monocytes, and natural killer cells have shown their numbers to peak midday or late in the day. Serum levels and in vitro production of interferon gamma (IFN-ɤ), tumor necrosis factor alpha (TNF-α), and IL-1, IL-2, IL-6, and IL-12 peak at night or early in the morning.
- Antigen presenting cells (APCs) are involved in the capture and processing of allergens and the subsequent presentation of pathogen-derived peptides to native T cells in the lymph nodes, tonsils, and adenoids. APCs are located in the superficial layers of the oral mucosa and consist of CD 207+ Langerhans cells and CD 11b+, CD 68+, and CD206+ macrophages located in the lamina propria. APCs capture allergens by phagocytosis and by IgE mediation, as they are FcεR1 positive. APCs exhibit a tolerogenic phenotype in that they produce IL-10 and TGF 13, and they express
indoleamine 2,3-dioxygenase. Macrophages secrete IL-10 and IL-12 andexpress retinaldehyde dehydrogenase 2 as a consequence in the absence of danger signals. The default response of oral APCs to allergens is intolerance as opposed to inflammation within the induction of IFN-ɤ producing and IL-10 secreting TH-1 and regulatory T cells (Tregs), respectively, in draining cervical lymph nodes. - Sleep supports the immunological synapse between APC and the T cells in lymph nodes. During sleep, there is increased production of pro-inflammatory Th1-supporting hormones such as melatonin, GH, prolactin, and leptin, whereas anti-inflammatory hormones such as cortisol and catecholamine reach a nadir. This pro-inflammatory hormonal boost during sleep acts like an adjuvant, presumably on APCs, which show a sleep-dependent production of IL-12, which in turn supports Th1 lineage commitment (Dimitrov et al., 2007; Lange et al., 2006, 2011). The regulatory role of APCs mediating the sleep-associated peak of T cell cytokine production is substantiated by the fact that the rhythm in cytokine production of isolated CD4+ T cells is shifted by several hours (Bollinger et al., 2011).
- In contrast, the initiation of a Th1 immune response that evolves more slowly requiring the interaction between APC and T cell in lymph nodes, protein biosynthesis, and cell proliferation is supported during sleep. The Th1 response is energy consuming and involves the release of pro-inflammatory mediators associated with pain, immobility, and malaise; therefore, its timing to the sleep period seems reasonable. B and T cells harbor an intrinsic clock, but additional regulatory influences of sleep, locomotor activity, hormonal changes, and APC activity entrain the rhythm of lymphocyte numbers and functions. In many, but not all in vivo studies, adaptive immune responses such as the delayed-type hypersensitivity reaction, as well as the T cell and antibody response to immunizations, benefit from sleep. Such a time-limited boost of lymphocyte activity may serve immune homeostasis and maximize efficiency of the immune system.
- The oral cavity contains an abundance of immunologically-active tissues (tonsils, adenoids, and lymph nodes). This expedites the process of efficient antigen presentation. The low concentration of mast cells guarantees safe allergen administration via vestibular immunotherapy. According to Allam (Allergy 2008), there is a substantial concentration of dendritic cells in the oral vestibular space.
- There is no current literature, guidelines, or recommendations regarding the management in patients who do not tolerate or have failed to respond to SCIT. Commonly, treatment is interrupted and patients continue to experience symptoms managed only with pharmacotherapy. Thus, there remains a need in the art for improved compositions and methods for treating allergic disease. The embodiments disclosed herein are aimed at overcoming these and other needs in the art.
- The inventor of the embodiments disclosed herein discovered a new and improved method for treating allergic disease, which includes, inter alia, treating a patient at night using the compositions and methods described herein. The inventor also discovered that treating a patient at night via the oral vestibular space is an ideal protocol for the delivery of allergen-specific immunotherapy and other immunologic intervention.
- Embodiments of the present disclosure include a method for treating an allergic disease, the method comprising administering daily to a person in need thereof a first dosage of an allergen, the first dosage applied to the person’s sublingual space and progressively increasing in concentration per day over a time period of about four weeks; and administering daily to the person a second dosage of the allergen, the second dosage applied to the person’s oral vestibular space and remaining at a constant concentration per over a time period of about twelve weeks; wherein the administering steps comprise administering the allergen at night.
- Another embodiment of the present disclosure includes a method for treating allergic disease, the method comprising providing a serum to a patient, the serum including at least one allergen; and instructing the patient to self-administer at night a dosage of the serum, the instructing including defining a treatment period having a first phase and a second phase, wherein the dosage progressively increases during the first phase, and wherein the dosage remains constant during the second phase; wherein in the first phase the patient self-administers the serum to its sublingual space, and wherein in the second phase the patient self-administers the serum to its oral vestibular space.
-
FIG. 1 is a depiction of a reduction in the total symptom score in patients treated in accordance with embodiments of the present disclosure; -
FIG. 2 is a depiction of increased adherence to treatment in patients treated in accordance with embodiments of the present disclosure; -
FIGS. 3A and 3B are depictions of a reduction in the total symptom score and adherence levels, respectively, in patients treated in accordance with embodiments of the present disclosure; -
FIG. 4 is a comparison of total symptom score changes between patients treated with prior art methods and patients treated in accordance with embodiments of the present disclosure; and -
FIG. 5 depicts changes in clinical parameters in 38 patients from inner city asthmatic patients treated with embodiments of the present disclosure. - The present invention will now be described more fully hereinafter with reference to the accompanying drawings, in which embodiments of the invention are shown by way of illustration and example. This invention may, however, be embodied in many forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art.
- The inventor discovered that embodiments of the present disclosure, as herein referred to as Nocturnal Immuno Vestibular Oral Therapy (“NIVOT”), are best delivered in two phases: (1) buildup and (2) maintenance. In one embodiment, administration requires a four-week build-up stage, during which incremental dosages are administered in the sublingual spaces. Alternatively, the build-up stage spans about one week, about two weeks, about three weeks, about five weeks, about six weeks, or any other time period deemed suitable depending upon the needs of the patient being treated. During this initial stage, patients hold the drops under the tongue for at least 10 minutes before swallowing, however other retention times are considered to be within the scope of the present disclosure. In a preferred embodiment, the dosages are delivered to the sublingual space during the buildup stage and later delivered to the vestibular space during a subsequent maintenance phase. Nocturnal administration, for example, after sundown or otherwise determined upon consideration of the circadian rhythm(s) and sleep cycle(s) of a patient to be treated, maximizes the benefits of the natural immunological circadian cycles and minimizes disruption of the attachment of allergens in the mixture from the oral mucosa by eating or drinking.
- Thus, embodiments of the present disclosure include a method for treating a person with allergic disease, the method comprising administering to the person’s sublingual space a first dosage of an allergen; and administering to the person’s oral vestibular space a second dosage of the allergen. In one embodiment, the allergen is administered at night so as to maximize the effectiveness of the treatment by exploiting the circadian rhythmicity of the patient’s immune system and reductions in oral mucosal disruptions during sleep.
- As is typical with known immunotherapeutic treatments for allergic disease, a concentration of the first dosage of the allergen may be increased over time, thereby permitting a gradual increase in the patient’s tolerance to the allergen. In this first treatment phase, the first dosage of the allergen may be administered over a time period of about 4 weeks. The second dosage of the allergen, administered during a second phase of the treatment, remains constant over time. By way of example, the second dosage is administered over a time period of about 12 weeks.
- Another embodiment includes a method for treating allergic disease, the method comprising providing an allergen to a person, and instructing the person to self-administer the allergen at night. The instructing may include defining a treatment period having a first phase and a second phase, wherein in the first phase the person self-administers the allergen to its sublingual space, and wherein in the second phase the person self-administers the allergen to its oral vestibular space. In the first phase, a dosage of the allergen progressively increases. In the second phase a dosage of the allergen is constant. As with the first embodiment disclosed, the first phase spans a time period of about 4 weeks, and the second phase spans a time period of about 12 weeks.
- Yet another embodiment includes a method for treating allergic disease, the method comprising administering an allergen to a subject’s oral vestibular space. Alternatively, the treatment may be self-administered by the subject thereof. In a self-administration protocol, the method includes providing an allergen to a subject, and instructing the subject to administer the allergen to an oral vestibular space. Further, the physician or other health professional may instruct subject to only administer the allergen at night.
- Still yet another embodiment includes a method for treating an allergic disease, the method comprising providing an allergen to a person, and instructing the person to administer the allergen in accordance with a treatment plan, the treatment plan having a first phase and a second phase, the first phase including administering the allergen to the person’s sublingual space, the second phase including administering the allergen to the person’s oral vestibular space.
- It will be understood by one of ordinary skill that time points for nocturnal administration of an allergen may vary, so long as the administration is timed to correlate with the subject’s immune system circadian cycles and/or sleep cycles as herein described or as otherwise understood in the art.
- The allergen may be any known allergen. By way of non-limiting example, the allergen may be at least one of a grass, an inhalant, a weed, a tree, a mold, or any other substance or extract thereof that causes an allergic reaction in a subject. For example, the grass allergen may be a component of, or extract from, a grass such as Bahia, Bermuda, Johnson, Rye, or Timothy grass, or any other known grass and/or an extract therefrom. Exemplary inhalants include D. Farinea, D. Pteronyssinus, cat epithelium, dog epithelium, and/or German or American cockroach. Exemplary weeds include short ragweed, marsh elder, dog fennel, mugwort, baccahris, lambs quarter, spiny pigweed, sheep sorrel, nettle, and/or English plantain. Exemplary trees include Virginia live oak, red cedar, bald cypress, Australian pine, Bayberry, sweet gum, box elder, American elm, E. sycamore, and/or red mulberry. Exemplary molds include alternaria, penicillum mix, Cladosporium, Aspergilus mix, Helminlthosporium, Curvularia, Fusarium, Epicoccum, Pullularia, Hormodendrum, horse, and/or rabbit.
- By way of non-limiting example, an embodiment of the present disclosure may be prepared and administered in accordance with the following procedure.
Vials vials weeks Vial 5, or “maintenance”, is started onweek 5 and continues for the duration of treatment with daily administration. The maintenance vials last for 3 months. - Once maintenance dosage is reached, administration is relocated to the oral vestibular space, which is the area between the buccal mucosa and the teeth. It extends posteriorly all the way to the 2nd and 3rd molar regions. This space is rich in dendritic cells, which are central antigen presenting cells for the immune processing of antigens. The maintenance dosage is one drop per vial per day, which is very easily accommodated in this small space. Patients are instructed to hold the drops in place for at least 10 to 20 minutes. Afterward, patients are instructed to move the retained allergen and saliva to the inner aspects of the upper and lower lips and buccal mucosa.
- The administration of oral immunotherapy has well-documented attachment of radiolabeled allergen to the sublingual mucosa that persists even after 24 hours of administration. Diurnal administration of vestibular immunotherapy is affected by drinking and eating, and this has led us to the use of nocturnal administration. We have associated vestibular administration of allergen mixes after the patient has completed the nightly oral hygiene process with improved efficacy that is evident in a relatively short period of time (1 month).
- This substantial modification allows the allergens to remain undisturbed in the vestibular mucosa for at least 8 hours, therefore allowing APCs and macrophages to have access to allergens without displacement by eating or drinking. Additionally, the potential of an immunological circadian cycle with better immunological efficiency during sleep clearly plays a role in the efficacy of nocturnal vestibular immunotherapy.
- Interruptions in treatment of less than 6 weeks are inconsequential and maintenance dosages can be resumed with no adverse effects. There have been no observed episodes of anaphylaxis or other adverse events with the embodiments disclosed. This modality of immunotherapy is very safe and well tolerated. In contrast, interruptions in SCIT become a very difficult clinical situation with no studies to show that the maintenance dose may be safely resumed without potential adverse effects.
- The embodiments disclosed are believed to induce a decrease in eosinophilic infiltrates and allergen-
specific Th2 CD 4+ T cell responses in target organs in parallel with induction of systemic Th1 and Treg responses, a decrease in specific IgE in serum and mucosa, and induction of allergen-specific IgA and IgG2. Thus, successful immunotherapy may be correlated with immune reorientation of existing allergen-specific Th2 responses toward Th1 and Treg protide. The embodiments disclosed also likely induce expression of C1q and stabilize in the blood of responders patients as well as down-regulation of markers oftype 2 DC (CD141 and OX-402). - Exemplary preparation of treatment sets. In one embodiment of the present disclosure, new NIVOT treatment sets comprising four 10 mL vials filled with allergens formulated specifically to each patient’s specific allergies according to skin testing (or any other determination) are prepared in accordance with the following protocol.
- Prior to starting, clean the work area with a surface disinfectant. Collect all the supplies needed for the creation of the treatment sets, including 10 mL empty vials, 5 mL empty scratch dropper vials, 1 mL 23 G × ½-inch mixing syringes, 5 mL syringe with an 18 G × 1-inch needle, 100 mL bottle of 50% glycerin diluent, 4 × 4-inch cotton pads, and 70% isopropyl rubbing alcohol.
- Before allergen stocks are created, all 50 mL allergen serum bottles and all 10 mL vials are disinfected with a 4 × 4-inch cotton pad soaked in rubbing alcohol. In a first 10 mL vial (vial A), a possible total of 13 separate extracts of allergens consisting of grasses and some weeds are mathematically divided into equal portions to fill a 10 mL vial. A second 10 mL vial (vial B), includes extracts of the rest of the weeds and all of the trees (a possible total of 12 allergens) and are again mathematically divided into equal portions to fill a 10 mL vial. In a third vial (vial C), a possible total of 11 extracts of allergens consisting of molds and cockroach mix (if applicable) are mathematically divided into equal portions to fill a 10 mL vial. In a fourth vial (vial D), a possible total of four extracts of allergens consisting of inhalants including cat, dog, and dust mites are mathematically divided into equal portions to fill a 10 mL vial. These 10 mL vials (vials A, B, C, and D) are hereinafter referred to as “stock” and can be used in the future to make additional maintenance compositions.
- Exemplary dilution protocol. Allergen stocks may be obtained from any commercial allergen supplier. After the stocks are made, they are lined up vertically starting from the bottom. The bottom vial is labeled as vial A and the top as vial D.
- Starting in the column next to the stocks, place five 5 mL unused empty dropper vials horizontally in order with the vial next to the stock (“maintenance”) being the least dilute, or strongest, and the vial farthest from the stock as the most dilute, or weakest. In total, every new patient receives up to 20 empty scratch dropper vials.
- The four 5 mL vials next to the 10 mL stock vials initially remain empty, as these vials will only contain allergen serum, not diluent. They are labeled “maintenance.” A first vial is labeled
vial # 4 and will contain a 1:1 dilution. Fill each vial in that column with 0.75 mL of diluent by extracting 0.75 mL of diluent from the diluent bottle using a 1 mL mixing syringe with an attached 23 G × ½-inch needle and dispensing 0.75 mL of diluent into each of the 4 vials (A through D, if applicable). - Starting from left to right, are vials labeled #3, which will contain a dilution of 1:10, vials labeled #2 which will contain a dilution of 1:100, and finally vials labeled #1 which will contain a dilution of 1:1000. Fill each of these vials with 2.25 mL of diluent by extracting 2 mL from the diluent bottle using a 5 mL mixing syringe with an attached 23 G × ½-inch needle and then extracting 0.25 mL from the diluent bottle using a 1 mL mixing syringe with an attached 23 G × ½-inch needle. Dispense the full 2.25 mL of diluent into each of the sets of vials labeled #1 through #3 (A though D, if applicable, for each set).
- After the diluent is inserted into all of the vials, the final step of the dilution process is adding the stock to the vials by extracting 0.75 mL of stock A using a 1 mL mixing syringe with a 23 G × ½-inch needle attached and dispensing 0.75 mL of stock into vial #4A for a dilution of 1:1. Repeat the process by extracting the same amount from stocks B, C, and D (if applicable) and dispensing it into the vials of set #4B, C, and D (if applicable).
- Using a new 1 mL mixing syringe with a 23 G × ½-inch needle attached, extract 0.25 mL of stock A and dispense it into the #3A vial for a dilution of 1:10. Repeat this process, extracting the same amounts from stocks B, C, and D (if applicable) and dispensing into the vials of set #3B, C, and D (if applicable).
- Using a 1 mL mixing syringe with a 23 G × ½-inch needle attached, extract 0.25 mL of the mixed contents of vial #3A and dispense it into vial #2A for a dilution of 1:100. You will repeat this process extracting the same amount from #2 B, C, and D (if applicable) and dispensing into the vials of set #3 B, C, and D (if applicable).
- Using a 1 mL mixing syringe with an attached 23 G × ½-inch needle, extract 0.25 mL of the mixed contents of vial #2A and dispense it into vial #1A for a dilution of 1:1000. Repeat this process with all of the vials in the #1 set (B, C, and D if applicable).
- Using a 5 mL syringe with an attached 18 G × 1-inch needle, extract 4.9 mL of stock A and dispense it into the empty dropper vial labeled #5A (also known as MAINT-1-DROP-DAILY) for a dilution of 1:01. Repeat this process, extracting the same amounts from stock B, C, and D (if applicable) and dispensing into the vials of set #5 B, C, and D (if applicable). The vials in
set # 5 are used for the patient’s first set of maintenance, which can last up to 3 months. - Exemplary storage procedure. After the dilutions are all finalized, they are ready to be packaged and refrigerated. Each set of vials is packaged in a 13 mm box with a 13 mm tray insert that can hold up to 6 vials. Each box will contain vials from the same dilutions and stock. There will be five boxes made per patient for each new treatment.
Box 1 will contain all of the vials from set #1 (1:1000), vials A through D (if applicable).Box 2 will contain all of the vials from set #2 (1:100), vials A through D (if applicable).Box 3 will contain all of the vials from set #3 (1:10), vials A through D (if applicable).Box 4 will contain all of the vials from set #4 (1:1), vials A through D (if applicable).Box 5 will contain all of the vials fromset # 5 “maintenance” (1.01), vials A through D (if applicable). - Each box is labeled with the patient’s first and last name, what number vial the box contains (#1, #2, etc.), and the expiration date of the vials. Each box will also have a red warning label that reads: “Keep out of reach of children. Keep refrigerated.” All boxes may be held together by a rubber band and must be refrigerated at 40° F. or less at all times. Boxes should only be removed from the refrigerator when in use for treatment.
- Alternative embodiment. In another embodiment, a new patient comes in for an allergy checkup. The patient is then scheduled for follow up visit, which involves skin test. The results of the skin test aid in a determination of what allergens the patient is allergic to. This skin test, in turn, informs the physician of which allergens to include in the treatment regimen. Thus, the identity of the allergens will be different for each patient depending on what they are allergic to.
- In one embodiment, the patient will have another follow up visit to pick up the drops (total 4 vials). The first vial drop may be administered at the clinic under a physician’s observation. If the patient is able to tolerate this first dosage without an adverse reaction, this first dosage will become the patient’s starter dose. If the patient has an adverse reaction to the starter dose, the starter dose is diluted and the procedure is initiated again. The first four vials are in increasing dosage and will last about one month.
- Once the patient is able to tolerate the drops we will start them on Maintenance dose after 1st month. This dosage will continue for 12 months.
- A chart retrospective review has been conducted on four patients with allergic rhinitis and one with asthma who were initially managed by Subcutaneous Immunotherapy (SCIT). These patients were treated with SCIT for an average of 11 months and due to lack of response were later switched to Nocturnal Immuno Vestibular Oral Therapy (NIVOT). Symptoms were quantified using the Total Symptom Score (TSS), a standard that is well known in the art..
- With reference to
FIG. 1 , the four patients experienced an average increase in TSS of 2.75 points while on SCIT. Within the first month of treatment in accordance with an embodiment of the present disclosure, an average decrease in TSS of 6.5 points was measured. One of the patients was affected with asthma and was frustrated with lack of response while on SCIT. In this case, after introduction to treatment in accordance with an embodiment of the present disclosure, we did not see a decrease in TSS but her Asthma Control Test (ACT) score improved by 12points 1 month after the introduction of NIVOT with no changes made to her asthma controller medications. NIVOT was tolerated without any adverse events in all four patients. -
FIG. 2 depicts patients’ improved adherence to the treatment protocol of the present disclosure as compared to adherence to treatment regimens by patients treated with SCIT. After 7 weeks of treatment, 87% of the patients treated in accordance with embodiments of the present disclosure were still adhering to the treatment protocol, whereas only 57% present of patients treated with SCIT were still undergoing treatment. In fact, improved adherence to treatment can be measured at as early as one week after initiation of the treatment protocol. -
FIG. 3A is a comparison of total symptom score between the general population, children, and Amerigroup® patients. The first maintenance doses were provided at one month after the start of treatment. As depicted, all three groups showed a substantial decrease in total symptom score, and that decrease was maintained for at least one year following the initiation of treatment in accordance with the embodiments of the present disclosure. As depicted inFIG. 3B , adherence levels for patients in this study were also within a desirable range. -
FIG. 4 is a comparison of total symptom scores between patients treated with the embodiments disclosed herein and patients treated with traditional SCIT. Patients in the two treatment groups each began treatment at a TSS of about 12-13. At the beginning of the first maintenance dose, patients exhibited comparable decreases in TSS. We observed an even further decrease in TSS at least one year after treatment. -
FIG. 5 depicts changes in clinical parameters in 38 patients from inner city asthmatic patients treated with embodiments of the present disclosure (FEV1: Forced Expiratory Volume in the first second of a pulmonary function test (“PFT”), wherein the amount of air blown in 1 second is measured; ACT: Asthma Control Test (commercially available); TSS: total symptom score). - In patients who fail to respond to SCIT, NIVOT administered at bedtime should be considered as a viable alternative in the management of these patients. Nocturnal administration may have an impact on the effectiveness of NIVOT due to immunological changes associated with the circadian cycle of the immune system.
- Although the invention has been described relative to various selected embodiments herein presented by way of example, there are numerous variations and modifications that will be readily apparent to those skilled in the art in light of the above teachings. It is therefore to be understood that, within the scope of the claims hereto attached and supported by this specification, the invention may be practiced other than as specifically described.
Claims (7)
1-16. (canceled)
17. A method for treating allergic disease in a human subject, the method comprising:
administering, at night, an allergen directly to a sublingual space.
18. The method of claim 17 , wherein the administering an allergen directly to a sublingual space comprises administering the allergen in multiple doses over a first period of time.
19. The method of claim 18 , wherein a concentration of the allergen increases over the first period of time.
20. The method of claim 17 , further comprising administering the allergen directly to an oral vestibular space.
21. The method of claim 20 , wherein the administering the allergen directly to an oral vestibular space comprises administering the allergen in multiple doses over a second period of time.
22. The method of claim 21 , wherein a concentration of the allergen remains constant over the second period of time.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/945,504 US20230256089A1 (en) | 2017-08-30 | 2022-09-15 | Immunotherapy For The Treatment Of Allergic Disease |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762552054P | 2017-08-30 | 2017-08-30 | |
US15/912,904 US10603376B2 (en) | 2017-08-30 | 2018-03-06 | Immunotherapy for the treatment of allergic disease |
US16/778,230 US11478546B2 (en) | 2017-08-30 | 2020-01-31 | Immunotherapy for the treatment of allergic disease |
US17/945,504 US20230256089A1 (en) | 2017-08-30 | 2022-09-15 | Immunotherapy For The Treatment Of Allergic Disease |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/778,230 Continuation US11478546B2 (en) | 2017-08-30 | 2020-01-31 | Immunotherapy for the treatment of allergic disease |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230256089A1 true US20230256089A1 (en) | 2023-08-17 |
Family
ID=65436425
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/912,904 Active US10603376B2 (en) | 2017-08-30 | 2018-03-06 | Immunotherapy for the treatment of allergic disease |
US16/778,230 Active US11478546B2 (en) | 2017-08-30 | 2020-01-31 | Immunotherapy for the treatment of allergic disease |
US17/945,504 Pending US20230256089A1 (en) | 2017-08-30 | 2022-09-15 | Immunotherapy For The Treatment Of Allergic Disease |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/912,904 Active US10603376B2 (en) | 2017-08-30 | 2018-03-06 | Immunotherapy for the treatment of allergic disease |
US16/778,230 Active US11478546B2 (en) | 2017-08-30 | 2020-01-31 | Immunotherapy for the treatment of allergic disease |
Country Status (1)
Country | Link |
---|---|
US (3) | US10603376B2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10603376B2 (en) * | 2017-08-30 | 2020-03-31 | Roberto Garcia-Ibanez | Immunotherapy for the treatment of allergic disease |
WO2022155653A1 (en) * | 2021-01-12 | 2022-07-21 | Morgan Sarah N | Vaccination and adaptive immune support protocol, formulation and method of use |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10603376B2 (en) * | 2017-08-30 | 2020-03-31 | Roberto Garcia-Ibanez | Immunotherapy for the treatment of allergic disease |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8491909B2 (en) | 2004-02-06 | 2013-07-23 | Greer Laboratories, Inc. | Methods and compositions for dosing of allergens |
US20060269576A1 (en) * | 2005-05-27 | 2006-11-30 | Curalogic, A/S | Non-injection immunotherapy |
ES2723173T3 (en) * | 2010-04-30 | 2019-08-22 | Allovate Llc | Toothpaste for allergic desensitization through the oral mucosa |
GB201104537D0 (en) | 2011-03-17 | 2011-05-04 | Cambridge Entpr Ltd | Treatment for peanut allergy |
-
2018
- 2018-03-06 US US15/912,904 patent/US10603376B2/en active Active
-
2020
- 2020-01-31 US US16/778,230 patent/US11478546B2/en active Active
-
2022
- 2022-09-15 US US17/945,504 patent/US20230256089A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10603376B2 (en) * | 2017-08-30 | 2020-03-31 | Roberto Garcia-Ibanez | Immunotherapy for the treatment of allergic disease |
US11478546B2 (en) * | 2017-08-30 | 2022-10-25 | Roberto Garcia-Ibanez | Immunotherapy for the treatment of allergic disease |
Also Published As
Publication number | Publication date |
---|---|
US20190060443A1 (en) | 2019-02-28 |
US11478546B2 (en) | 2022-10-25 |
US20200164063A1 (en) | 2020-05-28 |
US10603376B2 (en) | 2020-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230256089A1 (en) | Immunotherapy For The Treatment Of Allergic Disease | |
Nóbrega et al. | Low-level laser therapy for treatment of pain associated with orthodontic elastomeric separator placement: a placebo-controlled randomized double-blind clinical trial | |
Canonica et al. | Sub-lingual immunotherapy: World Allergy Organization position paper 2009 | |
Moingeon et al. | Immune mechanisms of allergen‐specific sublingual immunotherapy | |
Phillips et al. | Systemic reactions to subcutaneous allergen immunotherapy and the response to epinephrine. | |
US6255294B1 (en) | Cyanocobalamin (vitamin B12) treatment in allergic disease | |
Epstein et al. | Photobiomodulation therapy in the management of chronic oral graft-versus-host disease | |
de Oliveira Martins et al. | Laser therapy and pain-related behavior after injury of the inferior alveolar nerve: possible involvement of neurotrophins | |
US9655870B2 (en) | Homeopathic drug composition and methods of use thereof | |
Esch et al. | Methods and compositions for dosing of allergens | |
Aricigil et al. | New routes of allergen immunotherapy | |
KR20220148853A (en) | Formulations and uses thereof | |
JP6258200B2 (en) | DnaK dosage | |
Gabusi et al. | Surgical management of gingival recessions in patients with refractory gingival pemphigus vulgaris: A multidisciplinary challenge | |
EP2442828B1 (en) | Novel manner of administrating allergen in allergen specific immunotherapy | |
Fukuda et al. | Oral immunotherapy for allergic conjunctivitis using transgenic rice expressing hypoallergenic antigens | |
US10959450B2 (en) | Food composition for relieving symptoms of allergic and autoimmune diseases | |
ES2929631T3 (en) | Intradermal administration of an immunoglobulin G composition | |
RU2463015C1 (en) | Method of treating acute and chronic deep caries of teeth with complex medication | |
Canonica et al. | Sublingual and oral immunotherapy | |
Fiala et al. | Clinical and experimental treatment of allergic asthma with an emphasis on allergen immunotherapy and its mechanisms | |
Koshkareva et al. | Immunotherapy–Traditional | |
US20210023206A1 (en) | Composition for the treatment of type i allergic hypersensitivities by immune desensitization through slit immunotherapy with unadulterated allergen, vitamin a, vitamin d and an immuno-effective amount of adjuvant of essential oils | |
JP2009515983A (en) | Method for the treatment of fibrotic diseases by induction of immune tolerance | |
WO2002009747A1 (en) | Method for preventing and curing diseases of an immune system and a remedy for carrying out said method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |